D-galactose supplement for a specific inherited condition
Part of Genetic & congenital clinical trials.
This Phase 2 trial tests whether adding D-galactose can help people with a confirmed SLC35A2 genetic condition. It aims to improve symptoms such as seizures and ongoing stomach problems like vomiting or diarrhea.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a confirmed SLC35A2 genetic variant from a genetic test
- Be older than 1 month
- Currently have at least one symptom: seizures or chronic vomiting or chronic constipation or chronic diarrhea
- If you are a girl or woman over age 8, you must be using birth control during the study
- You must have had an eye exam within the past year
- A parent/guardian must be able and willing to consent if the participant cannot consent (for example, due to developmental disability)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether taking D-galactose is safe and helps symptoms or health markers in people with PGM1-CDG, a rare genetic condition. Participants must already be on a stable D-galactose dose to compare outcomes during the trial.
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
This trial tests whether taking fucose (a type of sugar) can help people with GLUT1 deficiency syndrome, a rare genetic condition that affects how the brain gets energy. If you have ataxia (trouble with balance or coordination) and meet other criteria, this study may be an option for you.
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
This trial tests whether giving a gene therapy before birth can help babies with GM1 gangliosidosis, a rare genetic disorder that damages the brain and body. It uses a harmless virus to deliver a working copy of the missing enzyme, aiming to slow or prevent disease progression.
This trial tests a new gene therapy (VGN-R08b) for infants with Type 2 Gaucher disease, a rare genetic condition that affects the brain and body. The goal is to see if the treatment is safe and can help improve symptoms.
Hear when a new SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.